How should we manage patients with mildly increased serum thyrotrophin concentrations?

• Published in: Clinical endocrinology (Oxford) Vol. 72; no. 4; pp. 436 - 440
• Main Author: Vanderpump, Mark P. J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2010; Blackwell; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Biological and medical sciences; Coronary Disease - etiology; Endocrinopathies; Female; Fundamental and applied biological sciences. Psychology; Hormones; Humans; Hypothyroidism; Hypothyroidism - complications; Hypothyroidism - drug therapy; Hypothyroidism - etiology; Male; Medical sciences; Middle Aged; Older people; Patients; Pregnancy; Thyroid Hormones - immunology; Thyrotropin - blood; Thyroxine - blood; Thyroxine - therapeutic use; Vertebrates: endocrinology; Human; Patient; Serum; Concentration; Thyrotrophin; Endocrinology
• ISSN: 0300-0664; 1365-2265; 1365-2265
• DOI: 10.1111/j.1365-2265.2009.03720.x

Summary A mildly increased serum thyrotrophin (TSH) is usually because of mild thyroid failure, and the most common aetiology in iodine‐replete communities is chronic autoimmune thyroiditis. It is more common in women, and the prevalence increases with age in both men and women and is associated with the presence of antithyroid antibodies. The majority will have serum TSH levels between 5–10 mIU/l, normal free thyroxine (T4) levels and relatively few symptoms. In 2004, US evidence‐based consensus guidelines concluded that there were no adverse outcomes of a mildly increased serum TSH other than a risk of progression to overt hypothyroidism and few data to justify levothyroxine therapy. There is still debate as to what constitutes an increased serum TSH, particularly in older subjects. Although some subjects will progress to overt hypothyroidism, recent data suggest a significant proportion revert to a serum TSH within the reference range without treatment. Two recent meta‐analyses have suggested that the possible cardiovascular risks may be more significant in younger adults. Other data suggest that mild thyroid failure may be the only reversible cause of left ventricular diastolic dysfunction. No appropriately powered prospective, randomized, controlled, double‐blinded interventional trial of levothyroxine therapy for a mildly increased serum TSH exists. However, treatment in subjects who are symptomatic, pregnant or preconception, aged less than 65 years and older subjects with evidence of heart failure appear justified.